Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

06.06.18	BIIB's Alzheimer's Drug Scores Well, EXAS Heads Higher, VXRT Down But Not Out (RTTNews)
05.06.18	Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases (PR Newswire)
05.06.18	Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months (PR Newswire)
31.05.18	Biogen Appoints Daniel Karp as EVP, Corporate Development (GlobeNewswire)
01.05.18	Biogen To Reduce Royalty Rates On Aducanumab; To Pay $50 Mln To Neurimmune (RTTNews)
24.04.18	Biogen Inc. Q1 adjusted earnings Beat Estimates (RTTNews)
24.04.18	Biogen Reports Quarterly Revenues of $3.1 Billion (Businesswire)
23.04.18	New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants (Businesswire)
23.04.18	BHVN In Focus, Fresenius Calls Off Deal To Buy AKRX, Good News For GUD (RTTNews)
20.04.18	Biogen, Ionis Expand Collaboration; Biogen To Pay $1 Bln To License Therapies (RTTNews)
20.04.18	Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases (Businesswire)
17.04.18	Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases (Businesswire)
05.04.18	Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization (RTTNews)
05.04.18	Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe (Businesswire)
28.03.18	Biogen to Report First Quarter 2018 Financial Results on April 24, 2018 (Businesswire)
15.03.18	Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting (Businesswire)
15.03.18	Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting (Businesswire)
12.03.18	MÄRKTE USA/Dow unter Druck - Nasdaq mit Rekord (Dow Jones)
12.03.18	MÄRKTE USA/Dow-Jones dreht ins Minus - Industriewerte schwach (Dow Jones)
12.03.18	MÄRKTE USA/Wall Street setzt Anstieg fort - Nasdaq auf Rekordhoch (Dow Jones)
12.03.18	MÄRKTE USA/Wall Street dürfte Anstieg fortsetzen (Dow Jones)
12.03.18	Biogen Announces New Interim Phase 2 Results From NURTURE (RTTNews)
12.03.18	Biogen kauft Pfizer Schizophrenie-Medikament in der Entwicklung ab (Dow Jones) Der US-Pharmakonzern Pfizer verkauft ein in der Entwicklung befindliches Schizophrenie-Medikament für bis zu 590 Millionen US-Dollar an Biogen.» mehr
12.03.18	Biogen To Acquire Phase 2b Ready Asset For Schizophrenia (RTTNews)
12.03.18	Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia (Businesswire)
12.03.18	New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen) (Businesswire)
07.03.18	Zinbrynta Now Connected To Brain Inflammation (RTTNews)
02.03.18	Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts (RTTNews)
02.03.18	Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis (Businesswire)
28.02.18	Biogen to Present at the Cowen and Company 38th Annual Health Care Conference (Businesswire)
14.02.18	The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy (Businesswire)
07.02.18	Biogen: Primary And Secondary Endpoints Not Met In Natalizumab Phase 2b Study (RTTNews)
07.02.18	Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke (Businesswire)
25.01.18	Biogen: Neues Medikament gegen Muskelschwund treibt Jahresumsatz in die Höhe (AWP) Der Biotechnologie-Konzern Biogen hat im vergangenen Jahr dank der Markteinführung eines neuen Mittels gegen Muskelschwund die eigenen Ziele übertroffen.» mehr
25.01.18	Biogen To Acquire Karyopharm's Investigational Oral SINE Compound KPT-350 (RTTNews)
25.01.18	Biogen Inc. Bottom Line Advances In Q4 (RTTNews)
22.01.18	Sanofi In Deal To Buy Hemophilia Drugmaker Bioverativ For $11.6 Bln; Stock Dips (RTTNews)
22.01.18	WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln (RTTNews)
19.01.18	MÄRKTE USA/Wall Street unbeeindruckt von drohendem "Shutdown" (Dow Jones)
19.01.18	MÄRKTE USA/Wall Street mit drohendem "Shutdown" kaum verändert (Dow Jones)
19.01.18	MÄRKTE USA/Wall Street legt trotz drohendem "Shutdown" leicht zu (Dow Jones)
19.01.18	MÄRKTE USA/Wall Street schiebt drohenden "Shutdown" in den Hintergrund (Dow Jones)
07.01.18	Pfizer stellt Forschung nach Alzheimer- und Parkinson-Mitteln ein (Dow Jones) Der Pfizer stellt die kostspielige und bisher erfolglose Entdeckung von Medikamenten für die Behandlung von Alzheimer und Parkinson ein.» mehr
04.01.18	Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing (Businesswire)
21.12.17	Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint (Businesswire)
20.12.17	Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018 (Businesswire)
20.12.17	EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours (RTTNews)
19.12.17	Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy (Businesswire)
18.12.17	Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

24.12.24		Börse New York: Dow Jones zeigt sich zum Handelsende fester
24.12.24		Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen
24.12.24		Dow Jones-Handel aktuell: Dow Jones steigt am Dienstagmittag
24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
24.12.24		NYSE-Handel: Dow Jones beginnt Dienstagshandel mit Gewinnen

24.12.24

Börse New York: Dow Jones zeigt sich zum Handelsende fester

24.12.24

Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen

24.12.24

Dow Jones-Handel aktuell: Dow Jones steigt am Dienstagmittag

24.12.24

Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu

24.12.24

Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50

24.12.24

Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone